7 research outputs found
Immunohistochemical Profile of Mucins and their Expression in Precancerous Changes of the Stomach
The aim of this study was to assess the profile of mucins (MUC1, MUC2, MUC5AC) in the intestinal metaplasia (IM) of the gastric mucosa through the immunohistochemical method. Methods: To identify the metaplastic areas in the gastric mucosa, chromoendoscopy was employed using 0.5% solution of methylene blue. The expression of the profile of the mucins was determined using immunohistochemistry with MUC1, MUC5AC, and MUC2 antibodies (clone Ma695, clone CLH2, Ccp58 and CLH5, "Novocastra "Great Britain). Results: In the regions adjacent to the adenocarcinoma and neoplastic modified cells, a visible weak expression of MUC2 and MUC5AC was observed. In the case of complete IM, a visibly maximum MUC2 expression was observed in the goblet cells; thus, the MUC5AC, MUC1, and MUC6 marking were absent in the columnar epitheliocytes with the brush border. In the case of incomplete IM, along with the positive MUC2 markings of the goblet cells, the presence of gastric mucin (MUC5AC) has been observed in 25% of such patients with chronic atrophic gastritis (CAG) having incomplete IM; however, in the columnar epitheliocytes the characteristic occurrence of gastric mucin (MUC5AC) was observed in 100% of the patients while a small amount of MUC2 was recorded in 15% of patients. Conclusion: The MUC5AC expression of the gastric mucins in the columnar epithelial cells and the goblet exocrinocytes marks the formation of the gastrointestinal phenotype viz., incomplete intestinal metaplasia, along with the simultaneous production of the MUC2 by the goblet cells. The decrease with further loss of the protective MUC5AC production by the columnar epithelial cells and goblet exocrinocytes that were found in the regions of severe dysplasia and IM, adjacent to the neoplastic altered cells, may serve as additional criteria of early malignancy of the gastric mucosa
ΠΠ»ΠΈΠΊΠΎΠ΄Π΅Π»ΠΈΠ½ β ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΠΉ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅Ρ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ ΠΎΠΏΡΡ ΠΎΠ»Π΅ΠΉ
Objective of the study to analyze and summarize the available data on the role of glycodelin in carcinogenesis and its expression in various cancers.Material and Methods. A literature search was conducted in Medline, PubMed Central, NCBI databases in the time interval from January 1983 to October 2019 using the key words glycodelin and cancer. Of the 104 publications found, 21 were used to write the review.Results. This paper presents the overview of the findings in current research focusing on the properties of glycodelin, the major lipocalin protein of the human reproductive system. Some lipocalins are known to play a key role in cancer development as well as influence signaling pathways in the regulation of cell motility, differentiation and neovascularization. Most likely they can be used as cancer markers. Glycodelin A is determined in serum and, due to its special immunoregulatory properties, can serve as a useful prognostic marker and a promising target for future anti-cancer therapies. The presence of glycodelin A in breast cancer tissue is known to be mostly linked to a better prognosis than is attributed to glycodelin-negative tissue, as glycodelin is a protein typical of differentiated tissue. On the other hand, glycodelin might play a role in neovascularisation, thereby promoting tumor growth. Glycodelin is a biomarker of aggressive malignant pleural mesothelioma and a prognostic biomarker of metastatic non-small cell lung cancer at late stages. Glycodelin hyperexpression is associated with brain metastasis in lung adenocarcinoma, and its determination can be used as an additional prognostic factor.Conclusion. The review refects basic scientifc data and results of clinical trials, as well as identifes future prospects that allow the development of new methods for cancer detection and treatment. It should be noted that glycodelin plays an important role in tumor development, progression, angiogenesis, and the formation of distant metastases, and therefore can serve as a useful diagnostic and prognostic marker. Further studies of the functional properties of glycodelin are needed to develop promising strategies in cancer therapy.Β Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β Π°Π½Π°Π»ΠΈΠ· ΠΈ ΠΎΠ±ΠΎΠ±ΡΠ΅Π½ΠΈΠ΅ ΠΈΠΌΠ΅ΡΡΠΈΡ
ΡΡ Π΄Π°Π½Π½ΡΡ
ΠΎ ΡΠΎΠ»ΠΈ Π³Π»ΠΈΠΊΠΎΠ΄Π΅Π»ΠΈΠ½Π° Π² ΠΊΠ°Π½ΡΠ΅ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ ΠΈ Π΅Π³ΠΎ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΏΡΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π²ΠΈΠ΄Π°Ρ
ΡΠ°ΠΊΠ°.ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠΎΠΈΡΠΊ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΡ
ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠ² ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΡΡ Π² ΡΠΈΡΡΠ΅ΠΌΠ°Ρ
Medline, PubMed Central, NCBI ΠΏΠΎ ΠΊΠ»ΡΡΠ΅Π²ΡΠΌ ΡΠ»ΠΎΠ²Π°ΠΌ glycodelin ΠΈ cancer. ΠΠ²ΠΈΠ΄Ρ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠΉ ΠΏΠΎ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΠΎΠΉ ΡΠ΅ΠΌΠ΅ Π°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π»ΠΈ Π²ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅, ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π½ΡΠ΅ Ρ ΡΠ½Π²Π°ΡΡ 1983 Π³. ΠΏΠΎ ΠΎΠΊΡΡΠ±ΡΡ 2019 Π³. ΠΠ· Π½Π°ΠΉΠ΄Π΅Π½Π½ΡΡ
Π½Π° ΡΡΡ ΡΠ΅ΠΌΡ 104 ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠΉ 21 Π±ΡΠ»Π° Π²ΠΊΠ»ΡΡΠ΅Π½Π° Π² ΠΎΠ±Π·ΠΎΡ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π ΡΠ°Π±ΠΎΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π½ΡΡ
ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ² ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠ³ΠΎ Π»ΠΈΠΏΠΎΠΊΠ°Π»ΠΈΠ½Π° ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° β Π³Π»ΠΈΠΊΠΎΠ΄Π΅Π»ΠΈΠ½Π°. ΠΠ·Π²Π΅ΡΡΠ½ΠΎ, ΡΡΠΎ Π½Π΅ΠΊΠΎΡΠΎΡΡΠ΅ Π»ΠΈΠΏΠΎΠΊΠ°Π»ΠΈΠ½Ρ ΠΈΠ³ΡΠ°ΡΡ ΠΊΠ»ΡΡΠ΅Π²ΡΡ ΡΠΎΠ»Ρ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΡΠ°ΠΊΠ°, Π° ΡΠ°ΠΊΠΆΠ΅ Π²Π»ΠΈΡΡΡ Π½Π° ΡΠΈΠ³Π½Π°Π»ΡΠ½ΡΠ΅ ΠΏΡΡΠΈ ΡΠ΅Π³ΡΠ»ΡΡΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΠΏΠΎΠ΄Π²ΠΈΠΆΠ½ΠΎΡΡΠΈ, Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΠΈ ΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ² Π½Π΅ΠΎΠ²Π°ΡΠΊΡΠ»ΡΡΠΈΠ·Π°ΡΠΈΠΈ. ΠΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎ, ΠΈΡ
ΠΌΠΎΠΆΠ½ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΎΠ½ΠΊΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ². ΠΠ»ΠΈΠΊΠΎΠ΄Π΅Π»ΠΈΠ½ Π ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΡΡΡ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΈ Π±Π»Π°Π³ΠΎΠ΄Π°ΡΡ ΡΠ²ΠΎΠΈΠΌ ΠΎΡΠΎΠ±ΡΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π³ΡΠ»ΡΡΠΎΡΠ½ΡΠΌ ΡΠ²ΠΎΠΉΡΡΠ²Π°ΠΌ ΠΌΠΎΠΆΠ΅Ρ ΡΠ»ΡΠΆΠΈΡΡ ΠΏΠΎΠ»Π΅Π·Π½ΡΠΌ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠΌ ΠΈ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΌΠΈΡΠ΅Π½ΡΡ Π΄Π»Ρ Π±ΡΠ΄ΡΡΠΈΡ
ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ². ΠΠ·Π²Π΅ΡΡΠ½ΠΎ, ΡΡΠΎ ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ Π³Π»ΠΈΠΊΠΎΠ΄Π΅Π»ΠΈΠ½Π° Π Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅Ρ Π²ΡΡΠΎΠΊΡΡ ΡΡΠ΅ΠΏΠ΅Π½Ρ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠΌ Π±ΠΎΠ»Π΅Π΅ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π°. Π ΡΠΎ ΠΆΠ΅ Π²ΡΠ΅ΠΌΡ ΠΎΠ½ ΠΈΠ³ΡΠ°Π΅Ρ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ ΡΠΎΠ»Ρ Π² Π½Π΅ΠΎΠ°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π·Π΅. ΠΠ»ΠΈΠΊΠΎΠ΄Π΅Π»ΠΈΠ½ ΡΠ²Π»ΡΠ΅ΡΡΡ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠΌ Π°Π³ΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠΉ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΌΠ΅Π·ΠΎΡΠ΅Π»ΠΈΠΎΠΌΡ ΠΏΠ»Π΅Π²ΡΡ, Π° ΡΠ°ΠΊΠΆΠ΅ Π²ΡΠΏΠΎΠΌΠΎΠ³Π°ΡΠ΅Π»ΡΠ½ΡΠΌ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠΌ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° Π»Π΅Π³ΠΊΠΈΡ
Π½Π° ΠΏΠΎΠ·Π΄Π½ΠΈΡ
ΡΡΠ°Π΄ΠΈΡΡ
. ΠΠΈΠΏΠ΅ΡΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π³Π»ΠΈΠΊΠΎΠ΄Π΅Π»ΠΈΠ½Π° Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π° Ρ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π² ΠΌΠΎΠ·Π³ ΠΏΡΠΈ Π°Π΄Π΅Π½ΠΎΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠ΅ Π»Π΅Π³ΠΊΠΈΡ
, ΠΈ Π΅Π΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΎ ΠΊΠ°ΠΊ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π ΠΎΠ±Π·ΠΎΡΠ΅ ΠΎΡΡΠ°ΠΆΠ΅Π½Ρ ΡΡΠ½Π΄Π°ΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΠ΅ Π½Π°ΡΡΠ½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΠ΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠΈΠ΅ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°ΡΡ Π½ΠΎΠ²ΡΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ. Π‘Π»Π΅Π΄ΡΠ΅Ρ ΠΎΡΠΌΠ΅ΡΠΈΡΡ, ΡΡΠΎ Π³Π»ΠΈΠΊΠΎΠ΄Π΅Π»ΠΈΠ½ ΠΈΠ³ΡΠ°Π΅Ρ Π²Π°ΠΆΠ½ΡΡ ΡΠΎΠ»Ρ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ, ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ, Π°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π·Π΅ ΠΈ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΎΠ² ΠΈ, ΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΠΎ, ΠΌΠΎΠΆΠ΅Ρ ΡΠ»ΡΠΆΠΈΡΡ ΠΏΠΎΠ»Π΅Π·Π½ΡΠΌ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠΌ. ΠΠ΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΠ΅ ΡΠ³Π»ΡΠ±Π»Π΅Π½Π½ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠ²ΠΎΠΉΡΡΠ² Π³Π»ΠΈΠΊΠΎΠ΄Π΅Π»ΠΈΠ½Π° Π΄Π»Ρ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΡΡΡΠ°ΡΠ΅Π³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΉ Π² ΠΎΠ½ΠΊΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ.
The influence of clinical, pathological and surgical factors on the occurrence of recurrence of borderline ovarian tumors in different age groups
Background. Borderline ovarian tumors (BOT), due to their unclear biological potential, remain a problem for oncogynecologists. On the one hand, frequent recurrences of tumors, and on the other hand, a high survival rate in the diagnosis of patients requires careful weighing of all risk factors when choosing surgical intervention tactics in patients with BOT. A large number of recurrences of BOT in patients of fertile age lead to disability of patients, deterioration of their quality of life and loss of reproductive function.Objective: evaluation of the influence of clinical and morphological factors (the presence of non-invasive implants, bilateral lesion of the ovaries, the presence of psammous bodies and malignization tricks) and surgical factors (damage to the cyst capsule and carrying out fertility preserving operations) on the recurrence of BOT in various age groups.Materials and methods. The material for the study was the protocols of an in vivo pathoanatomical study of a biopsy (surgical) material obtained from patients with a diagnosis of BOT for the period from 2000 to 2017 inclusive, according to the Regional Forensic Medical Bureau of Kursk. A total of 110 protocols for the first occurrence of BOT and 14 protocols for the tumor recurrences were analyzed. The age of patients undergoing an in vivo pathologic examination ranged from 19 to 75 years.Results and conclusions. It has been revealed that psammous bodies, fertility preserving operations and reproductive age are associated with tumor recurrence. Groups of patients with foci of malignancy and bilateral lesions have a lower risk of BOT recurrence due to the radical surgical treatment tactics and possibly the use of chemotherapy in the first case. Non-invasive implants are not associated with the risk of BOT recurrence
INTERCELLULAR AND CELL-MATRIX INTERACTIONS IN BREAST CARCINOMA: THE PRESENT STATE OF PROBLEM
In the article, based on the analysis of literature and own data, the study of intercellular and cell-matrix interactions in breast tumors was performed. The data considered in the article are important for understanding the processes of intercellular interaction and patterns of tumor growth, since tumor microenvironment plays an important role in the regulation of tumor state
COMPARATIVE IMMUNOHISTOCHEMICAL EVALUATION OF E-CADHERIN AND Ξ-KATENIN EXPRESSION IN METASTATIC AND NON-METASTATIC BREAST CANCER OF NON-SPECIFIC TYPE
Objective: an immunohistochemical analysis of the features of expression, distribution and interaction of E-Ρadherin and Ξ²-Ρatenin proteins in primary mammary tumors. Materials and methods. The study group consisted of 148 relevant patients with breast cancer (BC), including patients with metastases in lymph nodes (n = 12) and liver (n = 45). E-Ρadherin and Ξ²-Ρatenin expression on BC cells was determined using immunohistochemical method with specific antibodies. Results. It was shown that the reduction and the total absence of E-Ρadherin expression was observed much more often in patients with BC with metastases in liver, than in patients without metastases (70 % of cases versus 30 % of cases respectively). An increase of cytoplasmic immune reactivity and a nuclear translocation of Ξ²-Ρatenin are found in more than 80 % cases of BC with metastases.Conclusion. The changes in the expression of E-Ρadherin and Ξ²-Ρatenin in tumor cell can be considered as factors of a non-favorable prognosis of BC. The emergence of Ξ²-Ρatenin expression indicates the activation of a signaling pathway which is triggered by the aberrant expression of epithelial cadherins leading to an increased mobility and invasion of tumor cells